Globus Medical, Inc. $GMED Shares Sold by Prudential PLC

Prudential PLC reduced its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 25.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,037 shares of the medical device company’s stock after selling 7,243 shares during the quarter. Prudential PLC’s holdings in Globus Medical were worth $1,837,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. lifted its position in shares of Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 167 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Globus Medical by 2.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company’s stock worth $375,000 after purchasing an additional 170 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares in the last quarter. Finally, Allworth Financial LP raised its position in shares of Globus Medical by 1.6% in the fourth quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock valued at $1,095,000 after buying an additional 199 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical Stock Up 0.2%

GMED stock opened at $80.13 on Monday. The company has a market cap of $10.88 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 1.65 and a beta of 0.95. The business has a fifty day simple moving average of $86.27 and a 200-day simple moving average of $88.25. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same period in the previous year, the firm earned $0.68 earnings per share. Globus Medical’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on GMED shares. Needham & Company LLC lifted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Truist Financial set a $115.00 price target on Globus Medical in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.